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INTRODUCTION 
Recent developments in the technology have presented 
viable dosage alternatives from oral route for pediatrics, 
geriatric, bedridden, nauseous or noncompliant patients. 
Buccal drug delivery has lately become an important 
route of drug administration. Various bio adhesive 
mucosal dosage forms have been developed, which 
includes adhesive tablets, gels, ointments, patches and 
more recently the use of polymeric films for buccal 
delivery. The most popular solid dosage forms are being 
tablets and capsules. The conventional tablet seems to be 
most popular because of its ease of transportability and 
comparatively low manufacturing cost but poor patient 
compliance in case of pediatrics and geriatrics patients 
because of hand tremors and dysphasia that experienced 
difficulties in swallowing. Often times people experience 
inconvenience in swallowing conventional dosage forms 
such as tablet when water is not available, in the case of 
the motion sickness (kinetosis) and sudden episodes of 
coughing during the common cold, allergic condition and 
bronchitis. To overcome these problems, scientists have 
developed innovative drug delivery system known as fast 
dissolving/disintegrating tablets (FDTs). These are novel 
types of tablets that dissolve/ disintegrate/ disperse in 
saliva within few seconds. The Centre for Drug 
Evaluation and Research (CDER), US FDA defined fast 
dissolving/ disintegrating tablets (FDT) as  
“A solid dosage form containing medicinal substances, 
which disintegrates rapidly, usually within a matter of 
seconds, when placed upon the tongue”.  
Drugs release from FDT get absorbed from the oral 
cavity, pharynx and esophagus as the saliva passes down 
into the stomach. Dispersion of tizanidine hydrochloride 
in saliva in oral cavity causes pre-gastric absorption of 
drug which dissolves. Any pre-gastric absorption avoids 
first pass hepatic metabolism which also increases 
bioavailability.1, 2 
Tizanidine hydrochloride is an Imidazoline derivative 
which acts as agonist on centrally located α 2 receptors 
and this leads to myotonolytic effects on skeletal muscle. 
It is structurally and pharmacologically similar to 
Clonidine and other α-2 adrenergic agonists. It is given 
with a dose of 2-4 mg. About 53-66% of the dose 
administered is being absorbed through the 
gastrointestinal tract after oral administration and the 
peak plasma concentration is reached within 1 to 2 hrs. 
Bioavailability of Tizanidine is about 34-40% and half 
life is 2.5 hrs. The drug is widely distributed throughout 
the body and 30% of drug binds to plasma proteins. It 
undergoes rapid and extensive first pass metabolism in 
the liver (approximately 95% of a dose), leading to the 
oxidation of the Imidazole moiety, aromatic system and 
the sulphur atom. This leads to lower bioavailability of 
Tizanidine hydrochloride. It is a white to off white, fine 
crystalline powder, which is odourless or with faint 
characteristic odour. It is slightly soluble in water and 
methanol, solubility in water decreases as the pH 
increases. Its chemical IUPAC name is 5–Chloro–4-(2–
Imidazolin-2-ylamino)–2,1,3-benzothiodiazole 
hydrochloride.3, 4 
MATERIALS AND METHODS  
MATERIALS 
The research was carried out using instruments like 
Friability Test Apparatus, DSC 200F3, Dissolution Test 
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Apparatus (8 basket), UV Spectrophotometer 
(Shimadzu). Tizanidine (Pure drug) and excipient 
polymers (Crospovidone, Crosscarmellose Sodium, 
Sodium Starch Glycolate, Microcrystalline Cellulose 
Analytical grade, Vanillin, Talc and Magnesium 
Stearate) were provided by Nishka labs. Mannitol, 
Sodium Hydroxide and Potassium Dihydrogen Ortho 
Phosphate were bought from SD Fine, Mumbai. 
METHODS  
Direct compression method: Fast dissolving tablets of 
tizanidine hydrochloride were prepared by direct 
compression method. All the ingredients were passed 
through sieve no. 16. Then the ingredients were weighed 
and mixed in the plastic container in geometrical order 
and compressed into tablets of 100 mg.5  
EVALUATION 
1) PRE COMPRESSION PARAMETERS OF 
TIZANIDINE HYDROCHLORIDE FAST 
DISSOLVING TABLETS 
The prepared blend was analyzed for angle of repose, 
bulk density, tapped density, compressibility index and 
Hausner’s ratio. Determination of bulk density and 
tapped density:  
Flow Properties
 
Carr’s Index (Compressibility): The compressibility 
index is the measure of property of powder to be 
compressed. The packing ability of drug was evaluated 
from change in volume, which is due to rearrangement of 
packing occurring during tapping. It was indicated as 
Carr’s compressibility index.6 
Hausner Ratio: It is measurement of frictional 
resistance of the drug. The ideal range should be 1.2-1.5. 
It was determined by the ratio of tapped density and bulk 
density.6 
Angle of Repose:
 It is defined as the maximum angle 
that can be obtained between the free standing of powder 
heap and horizontal plane. Weighed quantity of the drug 
was passed through a funnel kept at a height 2 cm from 
the base. The powder was passed till it forms a heap and 
touches the tip of the funnel. The radius was measured 
and angle of repose was calculated.
7
  
2) DRUG -EXCIPIENTS COMPATIBLITY 
STUDIES
 
Fourier Transform Infrared Spectroscopy (FT-IR): 
The Fourier-transform infrared spectra of tizanidine 
hydrochloride and mixture of tizanidine hydrochloride 
with other excipients were obtained by using FTIR 
spectroscopy (Shimadzu, Japan). The samples were 
crushed with KBr to get pellets by applying pressure of 
600 Kg/cm2.8 
3) POST COMPRESSION PARAMETERS OF 
TIZANIDINE HYDROCHLORIDE FAST 
DISSOLVING TABLETS 
Evaluation parameters of tablets mention in the 
Pharmacopoeias need to be assessed, along with some 
special tests which are discussed here. 
Weight Variation: Weight variation test was performed 
by weighing 20 tablets individually, calculating the 
average weight and comparing the individual tablet 
weight to the average one, determinations were carried 
out in triplicate.9 
Hardness: The hardness of the tablets was determined 
using Monsanto Hardness tester. It is expressed in 
Kg/cm2.9 
Friability: Friability of the tablet determined using 
Roche friabilator. This device subjects the tablet to the 
combined effect of abrasion and shock in a plastic 
chamber revolving at 25 rpm and dropping a tablet at a 
height of 6 inches in each revolution. Pre weighted 
sample of tablets was placed in the friabilator and were 
subjected to the 100 revolutions. Tablets were de-dusted 
using a soft muslin cloth and reweighed.10  
Thickness: The thickness and diameter of the tablets 
was determined using a Vernier calliper. Three tablets 
from each type of formulation were used and average 
values were calculated. It is expressed in mm.10 
Water Absorption Ratio: A piece of tissue paper folded 
twice was kept in a Petri dish (internal diameter 5.5cm) 
containing 6ml of purified water. The tablet was placed 
on the tissue paper and allowed to wet completely. The 
wetted tablet was removed and reweighted.11  
Wetting Time: A piece of tissue paper folded twice was 
placed in a small Petri dish containing 6ml pH 6.8 
phosphate buffers. A tablet was placed on the paper and 
the time taken for complete wetting was noted.11 
Disintegration Study: In the Disintegration time study 
one tablet was placed in a beaker containing 10 ml of pH 
6.8 phosphate buffers at 37 ± 0.50 C and the time 
required for complete dispersion was determined.12 
Drug Content: Five tablets were randomly selected and 
average weight was calculated. Tablets were powdered 
in a glass mortar. Powder equivalent to 4 mg weight and 
dissolved in 100 ml of 6.8 pH buffer filtered and drug 
content analyzed spectrophotometrically at 230 nm.12 
In - Vitro Dissolution Testing: Dissolution study is 
conducted for all the formulation using USP type-II 
apparatus. The dissolution test is per-formed using 
900ml of phosphate buffer (pH 6.8) is taken as the 
dissolution medium at 50 rpm and 37 ±0.5°C. Ten ml of 
aliquots were periodically withdrawn and the sample 
volume was replaced with an equal volume of fresh 
dissolution medium. The samples should be analyzed 
spectrophotometrically.12 
KINETIC RELEASE STUDIES OF DISSOLUTION 
DATA 
Zero Order: It describes the systems where the drug 
release rate is independent of its concentration of the 
dissolved substance. A graph is plotted between the time 
taken on x-axis and the cumulative % of drug release on 
y-axis.13 
First Order: The data obtained are plotted as log 
cumulative percentage of drug remaining vs. time .13 
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RESULTS AND DISCUSSION 
Fast dissolving tablets of tizanidine hydrochloride were 
prepared by direct compression method by using 
superdisintegrants like crospovidone, crosscarmellose 
sodium and sodium starch glycolate in varying amount 
(Table 1). λmax of tizanidine in pH 6.8 was found to be at 
230 nm as shown in Figure 1. FT-IR studies: The FTIR 
spectra of the pure drug were recorded in between 4000 
to 400 cm-1. Characteristics peaks and chemical groups 
present in IR spectrum of tizanidine hydrochloride are 
shown in Figure 3. The FT-IR spectra of tizanidine 
hydrochloride revealed the presence of characteristic 
broad and strong peak for C=N  stretching around 
1644.98 cm-1, stretching peak around 3089.4 cm-1 
corresponds to the stretching vibration of C-H group and 
a strong band around 3245.61 cm-1 corresponds to N-H 
stretching. FTIR spectrum for tizanidine hydrochloride 
physical mixture is shown in Figure 4. Bulk density and 
tapped density: It ranges from 0.863±0.006 to 
0.880±0.010 (gm/cc) and 0.923±0.006 to 0.967±0.011 
(gm/cc) respectively. Compressibility index and Hausner 
ratio: It ranges from 4.695±0.641 to 10.686±0.466 and 
1.049±0.007 to 1.120±0.006 respectively. Angle of 
repose: It ranges from 22.441±0.570 to 28.762±0.9850, it 
show blend flows freely through the hopper.  The results 
for pre compressed parameters are shown in Table 2. 
Weight variation test: It ranges from 99.85±1.253 to 
101.71±2.531 mg as per IP specification. Hardness: It 
was in between 4.17±0.289 & 5.33±0.289 kg/cm2. The 
results indicate that the tablets are mechanically strong 
and are in limit. Thickness: It ranges from 1.203±0.021 
to 1.517±0.061 mm; the results indicate that the tablets 
are suitable for packing. Friability: It ranges from 
0.553±0.223 to 0.693±0.252 %, so the results indicate 
that the percentage losses were not more than 1.0%. So 
the tablet complies as per IP specifications. In-Vitro 
Disintegration time: Its value are in between 27.46±1.12 
& 59.37±0.93 seconds, the results indicate that 
disintegration time of tablet formulations TZN 1, TZN 2, 
TZN 3, TZN 4, TZN 5, TZN 6, TZN 7 and TZN 8 are 
within 1 minute. Wetting time: It ranges from 
66.07±1.30 to 153.97±1.00 seconds and water absorption 
ratio: It was found in between 61.37±1.26 & 
98.98±0.731. Content uniformity: It was found in 
between 97.47±0.681 & 99.17±0.586 %. The post 
compressed parameters are shown in Table 3&4. 
Dissolution Study in 6.8 pH phosphate buffer: 
Formulations TZN 1, TZN 2, TZN 3, TZN 4, TZN 5, 
TZN 6, TZN 7 and TZN 8  have a recorded zero order 
drug release  93.27 %,  94.50  %,  84.59 %, 85.85 %, 
92.04 %, 94.51 %, 98.84 %, and 98.82 % respectively at 
the end of 30 min, the results are shown in Figure 5. First 
order release plot of tizanidine hydrochloride fast 
dissolving tablet are shown in Figures 6. Regression and 
slope data of release kinetics of tizanidine hydrochloride 
fast dissolving tablets in concern of zero order, first 
order, Higuchi’s and Korsmeyer Peppa’s  are shown in 
table 5. Formulations with disintegration time and 
wetting time are shown in Figure 7. 
 
Table 1: Formulations composition of tizanidine hydrochloride fast dissolving tablets 
Ingredients (mg) 
Formulation Code 
TZN1 TZN2 TZN3 TZN4 TZN5 TZN6 TZN7 TZN8 
Tizanidine HCl 4 4 4 4 4 4 4 4 
Crospovidone 6.5 8.5 - - - - 6.5 - 
Crosscarmellose Sodium - - 6.5 8.5 - - 6.5 6.5 
Sodium Starch Glycolate - - - - 6.5 8.5 - 6.5 
Microcrystalline Cellulose 30 30 30 30 30 30 30 30 
D-mannitol 52.5 50.5 52.5 50.5 52.5 50.5 46 46 
Aspartame 3 3 3 3 3 3 3 3 
Vanillin 1 1 1 1 1 1 1 1 
Talc 1 1 1 1 1 1 1 1 
Mg Stearate 2 2 2 2 2 2 2 2 
Total 100 100 100 100 100 100 100 100 
 
Table 2: Evaluation of pre-compression parameters of powder blends of formulations 
Formulation 
Code 
Bulk Density ± 
S.D (gm/cc) 
Tapped Density 
± S.D (gm/cc) 
Carr’s 
Index ±S.D 
Hausner’s 
Ratio ± S.D 
Angle of Repose 
± S.D (Ө) 
TZN1 0.867±0.005 0.953±0.011 9.087±0.499 1.100±0.006 27.813±1.060 
TZN2 0.880±0.010 0.950±0.010 7.365±1.021 1.079±0.011 22.441±0.570 
TZN3 0.880±0.010 0.923±0.006 4.695±0.641 1.049±0.007 23.950±0.159 
TZN4 0.870±0.030 0.966±0.011 9.991±1.060 1.111±0.013 27.932±0.551 
TZN5 0.863±0.006 0.967±0.011 10.686±0.466 1.120±0.006 26.758±0.426 
TZN6 0.867±0.006 0.937±0.006 7.828±0.592 1.085±0.007 26.754±0.813 
TZN7 0.877±0.020 0.943±0.015 7.074±0.712 1.076±0.008 28.762±0.985 
TZN8 0.867±0.011 0.947±0.006 8.451±1.050 1.092±0.012 27.627±0.949 
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Table 3: Evaluation of post-compression parameters of tizanidine hydrochloride FDTs 
Formulation 
Code 
Avg. wt. of Tablet 
±S.D (mg) 
Hardness ±S.D 
(kg/cm
2
) 
Thickness ±S.D 
(mm) 
Friability ±S.D (%) 
TZN1 101.71±2.531 4.83±0.764 1.413±0.028 0.623±0.031 
TZN2 100.69±1.200 4.67±0.764 1.357±0.047 0.577±0.042 
TZN3 100.39±1.364 4.83±0.577 1.354±0.042 0.677±0.060 
TZN4 100.50±0.947 5.33±0.289 1.343±0.042 0.571±0.065 
TZN5 99.91±1.750 4.17±0.289 1.253±0.041 0.553±0.223 
TZN6 100.38±1.741 4.36±0.259 1.356±0.036 0.693±0.252 
TZN7 99.85±1.253 5.17±0.289 1.203±0.021 0.623±0.041 
TZN8 100.48±1.58 4.67±0.764 1.517±0.061 0.670±0.129 
 
Table 4: In-vitro disintegration time, wetting time, water absorption ratio and drug content of tizanidine 
hydrochloride FDTs 
Formulation 
Code 
In-Vitro Disintegration 
Time ±S.D (sec) 
Wetting Time (sec) 
±S.D 
Water 
Absorption Ratio (%) ±S.D 
Drug Content 
±S.D 
 
TZN1 32.41±0.71 123.31±1.16 73.46±1.01 98.003±0.689 
TZN2 27.77±0.71 98.40±0.87 70.50±0.83 97.477±0.681 
TZN3 48.23±1.35 134.77±1.44 86.27±1.16 99.052±0.445 
TZN4 45.17±1.33 112.83±1.89 98.98±0.73 98.433±0.834 
TZN5 59.37±0.93  153.97±1.00 82.07±1.55 99.173±0.586 
TZN6 50.97±0.29 119.67±0.55 90.57±0.81 97.803±0.703 
TZN7 29.51±0.56 70.55±0.76 67.21±1.68 99.017±0.608 
TZN8 27.46±1.12 66.07±1.30 61.37±1.26 98.861±0.945 
 
Table 5: Regression and slope data of release kinetics of tizanidine hydrochloride fast dissolving tablets 
Formulation code 
Mathematical models (release kinetics) 
Zero order 
kinetics 
First order 
kinetics 
Higuchi’s Peppa’s 
r
2
 r
2
 r
2
 r
2
 n 
TZN1 0.846 0.982 0.988 0.844 0.621 
TZN2 0.840 0.980 0.976 0.841 0.603 
TZN3 0.924 0.985 0.992 0.973 0.651 
TZN4 0.919 0.988 0.991 0.974 0.640 
TZN5 0.641 0.858 0.834 0.730 0.521 
TZN6 0.639 0.881 0.832 0.729 0.512 
TZN7 0.664 0.960 0.852 0.738 0.670 
TZN8 0.911 0.959 0.962 0.956 0.835 
        
  
Figure 1: λmax of tizanidine hydrochloride in pH 6.8 at 230nm    
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Figure 2: Calibration curve of tizanidine hydrochloride in pH 6.8 at 230nm 
 
 
Figure 3:  FT-IR spectrum of pure tizanidine hydrochloride 
 
 
Figure 4: FT-IR spectrum of tizanidine hydrochloride physical mixture 
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Figure 5: Zero order release plot of tizanidine hydrochloride fast dissolving tablets (TZN 1-8) 
 
 
Figure 6: First order release plot of tizanidine hydrochloride fast dissolving tablets (TZN 1-8) 
 
 
Figure 7: Disintegration and wetting time of different formulations 
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CONCLUSION 
Fast dissolving tablets of tizanidine were successfully 
prepared by direct compression techniques using selected 
superdisintegrants for the immediate action and effective 
therapy. FTIR studies revealed that there was no 
interaction between tizanidine hydrochloride and 
excipients used in tablet formulation. The prepared 
tablets were evaluated for various parameters like 
hardness, friability, drug content, in-vitro disintegration 
time, wetting time, water absorption ration and in-vitro 
dissolution. From the point of view of maximum drug 
release within 20 minutes, formulation TZN8 is the best 
and hence optimized formulation.  The results concluded 
that fast dissolving tablets of poorly soluble drug, 
tizanidine hydrochloride showed enhanced dissolution, 
may improved bioavailability and hence better patient 
compliance. 
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